USA - NASDAQ:CTMX - US23284F1057 - Common Stock
We assign a fundamental rating of 5 out of 10 to CTMX. CTMX was compared to 534 industry peers in the Biotechnology industry. CTMX has an excellent financial health rating, but there are some minor concerns on its profitability. CTMX has a expensive valuation and it also scores bad on growth.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 27.41% | ||
ROE | 40.02% | ||
ROIC | 25.08% |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | 30.56% | ||
PM (TTM) | 34.01% | ||
GM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Altman-Z | 3.85 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 4.2 | ||
Quick Ratio | 4.2 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 6.34 | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | 7.82 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
3.615
-0.12 (-3.34%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 6.34 | ||
Fwd PE | N/A | ||
P/S | 4.23 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 4.97 | ||
P/tB | 5.03 | ||
EV/EBITDA | 7.82 |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 27.41% | ||
ROE | 40.02% | ||
ROCE | 31.75% | ||
ROIC | 25.08% | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | 30.56% | ||
PM (TTM) | 34.01% | ||
GM | N/A | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | 0 | ||
Cap/Depr | 15.57% | ||
Cap/Sales | 0.17% | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 4.2 | ||
Quick Ratio | 4.2 | ||
Altman-Z | 3.85 |